Biotech consulting

We supported a biotechnology company in the realization of a state of the art in the field of oligonucleotides (oligonucleotides consist of short segments of nucleic acids: RNA or DNA). In a context of growth and consequently of evolution of its R&D activities, our client wanted to acquire oligonucleotides technologies or to establish a partnership with an expert company in the field.

Having a limited vision of this complex domain at a global level, our client called our team to carry out a state of the art aiming at identifying and characterizing existing technologies and players worldwide, in order to select a panel of technologies and associated players of interest for our client. In the end, our project enabled our client to start discussions with 3 key selected players and to decide on an important investment for the future of its Research & Development activities.

Alcimed worked with a major biotech player to understand the potential market opportunity of a new mRNA therapeutic in the cardiology space.

Alcimed analyzed the full picture of the targeted cardiac disease, detailing the epidemiology, economic burden, current standard of care, unmet therapeutic needs, and an understanding from key opinion leaders why so many potential therapeutics have already failed to show efficacy in the space. Based on this analysis, Alcimed was able to model what the potential peak sales would be for the new mRNA therapeutic based on how they would likely fare against the current and potential future competitor therapies in the space.

Our client was able to leverage Alcimed’s analysis to make crucial go/no go decisions on the R&D pipeline project, eventually leading to green lighting the program and landing a crucial development partnership with a major pharma player.

Alcimed assisted an American biopharmaceutical client in defining the launch strategy of its orphan drug in Europe, and then in structuring a concrete and operational plan, both at the level of the European region and at the level of each targeted country.

The launch plan is a roadmap for each of the company’s key functions (medical, marketing, production, regulatory, sales) and covers the period from pre-launch (before obtaining the MA – Marketing Authorization) to the first sales.

Today, our team is still involved in regularly updating the first plan defined with our client, according to internal or external developments around this orphan drug in several European countries.

We supported a biotech company specialized in gene therapy for rare diseases in one of its strategic development projects. Our client’s goal was to build a franchise in the field of neuro-ophthalmology for the next 5 years.

The main challenge being related to the nature of rare diseases (little or no information, a strong dispersion of patients, poorly optimized care pathways, strong disparities between geographies…), we assisted our client in a commercial pre-evaluation on 3 rare ophthalmic diseases: description of the disease, epidemiological analysis, diagnosis and treatment practices, competitive landscape, unmet needs,… in order to guide our client towards commercial opportunities, indicate how to address them, and recommend the opportunity to work on in priority.

One of our clients, a major player in gene therapy, wanted to understand how to change its portfolio strategy by engaging in new therapeutic areas.

To this end, Alcimed carried out 7 opportunity assessments for different diseases by identifying their potential (disease severity, impact on the healthcare system, opportunity for gene therapy, patient population, etc.) and the associated risk (current treatments, risks for gene therapy linked to the healthcare structure already in place, feasibility of a clinical trial, etc.).

With the business cases built, the new therapeutic areas considered were compared and prioritized, the synergies evaluated, in order to orient our client’s developments in a portfolio logic.

A leading pharmaceutical client had launched a medical center of excellence in mRNA in 2021 that was dedicated to vaccines, with the objective of accelerating the development and delivery of next-generation vaccines. Our client wanted to maintain this dynamic by opening a medical center of development for mRNA technologies dedicated to preclinical, clinical, and translational research activities.

Our team initially identified public and semi-public financing opportunities for this project, then characterized them (concerned domains, eligibility criteria, funding amount, etc.) and selected the best opportunities by taking into account the needs and specific context of the client. Finally, Alcimed equally supported the client in developing their roadmap in this new R&D center.